QualityStocksNewsBreaks Archives - Page 532 of 1449

ThursdayDec 30, 2021 10:02 am

QualityStocksNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Settles Debt, Completes Refinance, Grants Stock and Options

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, has issued 6,784,812 shares to settle a CAD$5.1 million (US$4.0 million) debt. By settling the debt at a favorable conversion price (approximately CAD$0.75 or US $0.56 per share), RWB will realize an accounting gain of approximately CAD$2.3 million (US$1.8 million). Further to its April 28 press release, RWB has refinanced the CAD$12.8 million (U.S.$10 million) principal amount of its “Seven month” vendor take-back note issued to High Street Capital Partners LLC, in connection with RWB Florida LLC’s acquisition of all of the…

ThursdayDec 30, 2021 9:56 am

QualityStocksNewsBreaks – DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF) Unveils New Division Focused on ESG; Announces Investment in MADA Analytics

DigiMax Global (CSE: DIGI) (OTC: DBKSF) has entered the Environmental, Social and Governance (“ESG”) sector. The company made this strategic move by launching an ESG Solutions Division that will use artificial intelligence (“AI”) and predictive analytics to enable investors to make better investment decisions and assist developers in lowering their cost of capital. The company anticipates immediately aiding green-energy development and operations as they track and predict carbon credit arbitrage and trading opportunities around the globe. DIGI may also offer large investors assistance in monitoring and evaluating ESG opportunities and trends. One of DigiMax’s initial steps in this new space is…

WednesdayDec 29, 2021 12:48 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Approval from Independent Review Board for DehydraTECH-CBD Human Clinical Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board ("IRB") approval for its planned DehydraTECH-CBD human hypertension study HYPER-H21-4; the approval was received earlier than anticipated. The study is designed to "de-risk" outcomes prior to the company’s planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease. The six-week study, which is entirely funded through the existing cash resources, is planned to include 60 volunteers, aged 45 to 70, using three 150 mg doses of DehydraTECH-CBD daily for the duration of the study. Dosing…

WednesdayDec 29, 2021 12:16 pm

QualityStocksNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Solutions to Empower People to Take Charge of Their Health, Well-Being

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. Since its founding in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved to create wearable technologies and digital health care solutions that encourage and empower people to take charge of their health and well-being. “The company’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible continuous glucose monitor (‘CGM’) designed to help people with diabetes and prediabetes manage…

WednesdayDec 29, 2021 11:56 am

QualityStocksNewsBreaks – Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (FRA: 7CR) Continuing Strong Growth in iGaming Space

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF) (FRA: 7CR), a propriety software-as-a-service “SaaS” technology company delivering mobile live dealer technology to online gaming operators globally, is emerging as a clear leader in the burgeoning iGaming space. Most recently, the company announced that its total player wagering for November 2021 increased approximately 12% compared to October 2021. Further, monthly active player numbers are up 28%, bet spots have increased over 22%, and the company added three new operators to its platform. This brings the total number of operators using Playgon tech to 26, with eight more waiting in the wings at various…

WednesdayDec 29, 2021 11:47 am

QualityStocksNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Advancing as Innovator in DTC Hearing Aid Market

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer (“DTC”) hearing technology space, recently announced its acquisition of Hearing Assist II LLC (“HearingAssist”). A long established leader in the market, HearingAssist has sold over 500,000 hearing aids since 2008 and has generated upwards of $72 million in top-line revenues since 2018, transforming into Walmart’s largest hearing aid supplier in the process. The acquisition will enable InnerScope to accelerate its revenue and growth strategy, as it consolidates the sales generated by HearingAssist’s hearing product kiosks, which are currently in place across 757 Walmart stores in five states.…

WednesdayDec 29, 2021 11:32 am

QualityStocksNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Taking Part in POC Testing Revolution with HealthTab(TM)

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is positioning in an era where point-of-care (“POC”) testing offers numerous benefits, including faster results, lower costs, improved monitoring and medication adherence, and more. In the shift to a more decentralized testing approach, Avricore is taking part in this disruption through its POCT platform, HealthTab(TM), found at select community pharmacies. “HealthTab combines point-of-care analyzers that screen for over 20 biomarkers with a consumer-facing interface that displays results,” reads a recent article. “The analyzers screen for more than 20 biomarkers associated with select chronic and infectious diseases and communicate them in real-time with patients and…

WednesdayDec 29, 2021 10:52 am

QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Partners with DSA Systems for OTA Tech, Vehicle System Diagnostics

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced a key partnership with DSA Systems, a leading international provider of vehicle system diagnostics and remote OTA technology. The partnership calls for the two companies to collaborate on Mullen’s strategic FIVE EV Crossover Program. MULN is working on its Mullen FIVE offering, which is built on an EV crossover skateboard platform that provides multiple powertrain configurations and trim levels in a design that is Strikingly Different(TM). In the announcement, MULN noted that DSA is a global leader in equipping automotive OEMs with vehicle diagnostics and connectivity, building a renowned…

WednesdayDec 29, 2021 10:22 am

QualityStocksNewsBreaks – Consolidated Uranium Inc. (TSX.V: CUR) (OTCQB: CURUF) Releases Update through Shareholder Letter

Consolidated Uranium (TSX.V: CUR) (OTCQB: CURUF) CEO Philip Williams has shared a letter written to shareholders providing an overview of the company achievements for this year as well as objectives moving forward. The letter notes the continued uranium market resurgence and the positive impact this has had on share prices for uranium equites. In the letter, Williams noted that the company expects uranium prices, both spot and long term, will continue to rise. In addition, Williams observed that CURUF’s business model was to acquire and develop uranium projects around the globe. He further stated that the company intends to be an…

TuesdayDec 28, 2021 1:41 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Witnessing Swift Advancement in R&D Pipeline, Overall Business

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating report for Q2 2021, with notable company milestones and achievements highlighted. The company plans to move through the ongoing remaining preclinical studies for its CYB003 novel deuterated psilocybin analog and submit an investigational new drug application and clinical trial application in the second quarter of 2022 in the U.S. and the U.K., respectively. “Other notable company achievements during the quarter include the U.S. Drug Enforcement Agency’s approval of a Schedule I manufacturing license for Cybin’s…

Site Search

Company Search

Category: QualityStocksNewsBreaks